Siga Technologies Shares Outstanding 2006-2019 | SIGA

Siga Technologies shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Siga Technologies Annual Shares Outstanding
(Millions of Shares)
2018 83
2017 79
2016 57
2015 54
2014 53
2013 52
2012 52
2011 54
2010 45
2009 37
2008 35
2007 33
2006 28
2005 25
Siga Technologies Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 82
Q2 2019 82
Q1 2019 82
Q4 2018 83
Q3 2018 83
Q2 2018 81
Q1 2018 79
Q4 2017 79
Q3 2017 79
Q2 2017 79
Q1 2017 79
Q4 2016 57
Q3 2016 54
Q2 2016 54
Q1 2016 54
Q4 2015 54
Q3 2015 54
Q2 2015 54
Q1 2015 54
Q4 2014 53
Q3 2014 54
Q2 2014 53
Q1 2014 53
Q4 2013 52
Q3 2013 53
Q2 2013 52
Q1 2013 52
Q4 2012 52
Q3 2012 52
Q2 2012 52
Q1 2012 52
Q4 2011 54
Q3 2011 52
Q2 2011 55
Q1 2011 50
Q4 2010 45
Q3 2010 46
Q2 2010 44
Q1 2010 43
Q4 2009 37
Q3 2009 38
Q2 2009 37
Q1 2009 36
Q4 2008 35
Q3 2008 35
Q2 2008 35
Q1 2008 34
Q4 2007 33
Q3 2007 34
Q2 2007 41
Q1 2007 33
Q4 2006 28
Q3 2006 28
Q2 2006 27
Q1 2006 27
Q4 2005 25
Q3 2005 25
Q2 2005 25
Q1 2005 25
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.383B $0.477B
SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses, dengue virus, and the filoviruses.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $67.550B 39.07
Takeda Pharmaceutical (TAK) Japan $58.571B 10.38
Astellas Pharma (ALPMY) Japan $32.091B 16.03
Eisai (ESALY) Japan $22.967B 44.28
UCB SA (UCBJF) Belgium $18.867B 0.00
Grifols, S.A (GRFS) Spain $17.622B 23.09
Merck (MKGAF) Germany $17.318B 23.63
Neurocrine Biosciences (NBIX) United States $9.609B 266.97
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.636B 35.53
Ionis Pharmaceuticals (IONS) United States $8.509B 17.23
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.627B 9.74
IPSEN SA ADR (IPSEY) France $6.090B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.877B 0.00
Orion OYJ (ORINY) Finland $5.871B 0.00
STADA ARZNEIMI (STDAF) Germany $5.543B 0.00
Hypermarcas (HYPMY) Brazil $5.178B 15.75
United Therapeutics (UTHR) United States $4.694B 0.00
Nektar Therapeutics (NKTR) United States $4.139B 0.00
Evotec AG (EVTCY) Germany $4.138B 66.78
FibroGen (FGEN) United States $3.968B 116.61
Arrowhead Pharmaceuticals (ARWR) United States $3.913B 72.62
Sage Therapeutics (SAGE) United States $3.603B 0.00
PTC Therapeutics (PTCT) United States $3.524B 0.00
ChemoCentryx (CCXI) United States $2.837B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.802B 11.34
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.277B 0.00
Pacira Pharmaceuticals (PCRX) United States $2.024B 55.74
Xencor (XNCR) United States $1.995B 60.64
Tilray (TLRY) Canada $1.947B 0.00
Heron Therapeutics (HRTX) United States $1.932B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.840B 22.36
Corcept Therapeutics (CORT) United States $1.553B 17.42
USANA Health Sciences (USNA) United States $1.525B 15.94
Theravance Biopharma (TBPH) Cayman Islands $1.463B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.392B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.391B 9.49
Endo (ENDP) Ireland $1.377B 2.53
Zogenix (ZGNX) United States $1.335B 0.00
Akebia Therapeutics (AKBA) United States $1.207B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.060B 32.84
Portola Pharmaceuticals (PTLA) United States $1.051B 0.00
Karyopharm Therapeutics (KPTI) United States $1.010B 0.00
Aerie Pharmaceuticals (AERI) United States $1.000B 0.00
Radius Health (RDUS) United States $0.894B 0.00
ImmunoGen (IMGN) United States $0.810B 0.00
Collegium Pharmaceutical (COLL) United States $0.802B 0.00
Flexion Therapeutics (FLXN) United States $0.661B 0.00
Molecular Templates (MTEM) United States $0.659B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.571B 0.00
TherapeuticsMD (TXMD) United States $0.559B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.537B 65.13
Ardelyx (ARDX) United States $0.528B 0.00
Translate Bio (TBIO) United States $0.474B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.470B 20.27
Organogenesis Holdings (ORGO) United States $0.458B 0.00
Innate Pharma SA (IPHYF) France $0.446B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.419B 0.00
DURECT (DRRX) United States $0.417B 0.00
Calithera Biosciences (CALA) United States $0.402B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.386B 0.00
Recro Pharma (REPH) United States $0.384B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.378B 0.00
Harpoon Therapeutics (HARP) United States $0.377B 0.00
Lannett Co Inc (LCI) United States $0.369B 5.94
Indivior (INVVY) United States $0.356B 2.11
Corbus Pharmaceuticals Holdings (CRBP) United States $0.355B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.352B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.343B 0.00
Rafael Holdings (RFL) United States $0.333B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.330B 0.00
Concert Pharmaceuticals (CNCE) United States $0.327B 0.00
OptiNose (OPTN) United States $0.310B 0.00
Ocular Therapeutix (OCUL) United States $0.272B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.269B 0.00
MEI Pharma (MEIP) United States $0.251B 0.00
KalVista Pharmaceuticals (KALV) United States $0.249B 0.00
IMV INC (IMV) Canada $0.238B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.221B 0.00
Nature's Sunshine Products (NATR) United States $0.199B 34.30
Taiwan Liposome (TLC) Taiwan $0.195B 0.00
Jounce Therapeutics (JNCE) United States $0.175B 2.35
Galmed Pharmaceuticals (GLMD) Israel $0.130B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.125B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.123B 0.00
Xeris Pharmaceuticals (XERS) United States $0.118B 0.00
CannTrust Holdings (CTST) Canada $0.117B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.114B 0.00
Otonomy (OTIC) United States $0.109B 0.00
Redhill Biopharma (RDHL) Israel $0.107B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.106B 0.00
Aquestive Therapeutics (AQST) United States $0.106B 0.00
CV Sciences (CVSI) United States $0.087B 0.00
Infinity Pharmaceuticals (INFI) United States $0.083B 0.00
Neos Therapeutics (NEOS) United States $0.082B 0.00
Champions Oncology (CSBR) United States $0.081B 0.00
MediWound (MDWD) Israel $0.081B 0.00
Onconova Therapeutics (ONTX) United States $0.074B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.068B 20.45
Entasis Therapeutics Holdings (ETTX) United States $0.068B 0.00
CTI BioPharma (CTIC) United States $0.068B 0.00
SCYNEXIS (SCYX) United States $0.064B 0.00
Nivalis Therapeutics (ALPN) United States $0.060B 0.00
Aclaris Therapeutics (ACRS) United States $0.060B 0.00
RENEURON GP (RNUGF) United Kingdom $0.059B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.053B 0.00
VAXART, INC (VXRT) United States $0.052B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.052B 0.00
Natural Alternatives (NAII) United States $0.051B 23.03
Forward Pharma (FWP) Denmark $0.049B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.047B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.046B 0.00
PolarityTE (PTE) United States $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.042B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.039B 0.00
Mannatechorporated (MTEX) United States $0.037B 0.00
Jaguar Animal Health (JAGX) United States $0.036B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.029B 0.00
Vical (BBI) United States $0.027B 0.00
Biomerica (BMRA) United States $0.027B 0.00
PharmAthene (ALT) United States $0.027B 0.00
China SXT Pharmaceuticals (SXTC) China $0.026B 0.00
ProPhase Labs (PRPH) United States $0.020B 0.00
Bio-Path Holdings (BPTH) United States $0.018B 0.00
Regulus Therapeutics (RGLS) United States $0.017B 0.00
Cardiome Pharma (CORV) Canada $0.016B 0.00
Shineco (TYHT) China $0.016B 0.00
Heat Biologics (HTBX) United States $0.015B 0.00
Novan (NOVN) United States $0.015B 0.00
HANCOCK JAFFE (HJLI) United States $0.013B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.013B 0.00
Lipocine (LPCN) United States $0.012B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
RXi Pharmaceuticals (PHIO) United States $0.002B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00